Local recurrence after curative radiation therapy or postoperative radiotherapy for prostate cancer remains a challenging clinical scenario, requiring careful evaluation to balance disease control with the risk of treatment-related adverse events. Reirradiation has progressively emerged as a clinically meaningful salvage option for appropriately selected patients with localized recurrence. The widespread implementation of multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography-computed tomography has transformed clinical decision-making by enabling earlier detection of recurrence, more accurate localization of disease, and improved identification of patients who may benefit from focal salvage approaches. In this setting, multidisciplinary evaluation and careful patient selection are essential. Among available reirradiation techniques, photon-based stereotactic body radiotherapy currently has the largest body of supporting clinical evidence, while brachytherapy remains a valid alternative in experienced centers and protontherapy may offer additional opportunities to improve dose conformity in selected cases. Although oncological outcomes are encouraging, the available evidence remains predominantly retrospective and heterogeneous, highlighting the need for prospective studies and standardized treatment strategies. This commentary synthesizes contemporary evidence on re-irradiation for locally recurrent prostate cancer after both definitive and postoperative radiation therapy, with a particular focus on patient selection, treatment techniques, oncological outcomes, treatment-related adverse events, and emerging future directions.